Replies to post #197642 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

The point I am making is one of managing risk/reward ratio in a portfolio.

I agree you cannot determine a specific chance of success of any one biotech/drug/indication, only a probability assignment to each and the likely reward of success.

If done well the portfolio gives a positive return.

Now I hope Anavex succeed for all those CNS patients who could benefit, but from an invest perspective I don’t care which specific investment in my portfolio are the winners and losers.

The one thing I am sure of is that I can’t win with them all.

[XenaLives]

Based on my understanding of the science, there should be a response in all three trials. The response may not be the same response though, and there is where it gets interesting...

Response in all three would mean that 2-73 will probably have a positive effect in all "psychiatric" and CNS disease. Perhaps this should be phrased as all epigenetic disease.

I put "psychiatric" in quotes because the label seems improper in light of this information.

psychiatry (n.)
1846, from French psychiatrie, from Medieval Latin psychiatria, literally "a healing of the soul," from Latinized form of Greek psykhe "mind" (see psyche) + iatreia "healing, care" (see -iatric).

https://www.etymonline.com/word/psychiatry

Contemporary psychiatry has a Freudian root which has become completely obsolete. There needs to be a complete overhaul of the field and it should be joined to physiology and neurology.

Mind and body can not be treated separately any more.